GLP-1 receptor agonists × glycemic control

TrialDiabetes, obesity & metabolism2020

Liraglutide as add-on to sodium-glucose co-transporter-2 inhibitors in patients with inadequately controlled type 2 diabetes: LIRA-ADD2SGLT2i, a 26-week, randomized, double-blind, placebo-controlled trial.

Lawrence Blonde et al.PubMed ↗Full text ↗Publisher ↗

What the trial testedrandomised · 303 people · 2020

Randomised comparison

Probably lowered glycemic control

−0.68percentage points−0.89 to −0.48

As reported

difference −0.68 %, 95% CI −0.89 to −0.48

One number in the abstract

the abstract, start to end

(estimated treatment difference [ETD]: -0.68% [95% CI: -0.89, -0.48];

← favours treatmentfavours comparator →
could be chance
Glycemic control
−0.68−0.89 to −0.48
GLP-1 receptor agonistsGlycemic control

GLP-1 receptor agonists × glycemic controlhelps?replicated

unlikelylikely
0.910.91 without it
← favours treatmentfavours comparator →
this paperthis papermore certainless certain
1 / 5

26 papers cite it

2020
2021
2022
2023
2024
2025
2026
this paperpooled ittrialcites it

The trial

Full record →Abstract, authors, funding and every citing paper · PMID 31984646